

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2566)

VOLUNTARY ANNOUNCEMENT

JY54 INJECTION OBTAINED CLINICAL TRIAL APPROVAL IN CHINA

This announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the JY54 Injection (the “**Product**”), developed by the Group, has obtained approval from the National Medical Products Administration of the People's Republic of China (the “**NMPA**”) to conduct clinical trials in China.

The Product, by mimicking the mechanism of action of natural amylin and binding to amylin receptors, exerts multiple biological effects such as inhibiting glucagon secretion, delaying gastric emptying and reducing appetite, thereby contributing to glycemic control and weight management. Preclinical studies have shown that the Product has demonstrated excellent performance in both pharmacodynamic and safety studies, and is expected to show good therapeutic efficacy in subsequent clinical trials.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

FU Hang

Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, April 28, 2026

As at the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.